These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14725596)

  • 1. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study.
    Serra-Mestres J; Ring HA; Costa DC; Gacinovic S; Walker Z; Lees AJ; Robertson MM; Trimble MR
    Acta Psychiatr Scand; 2004 Feb; 109(2):140-6. PubMed ID: 14725596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT.
    Nikolaus S; Wirrwar A; Antke C; Arkian S; Schramm N; Müller HW; Larisch R
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):308-13. PubMed ID: 15791440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
    Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
    Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder.
    Malison RT; McDougle CJ; van Dyck CH; Scahill L; Baldwin RM; Seibyl JP; Price LH; Leckman JF; Innis RB
    Am J Psychiatry; 1995 Sep; 152(9):1359-61. PubMed ID: 7653693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers.
    Lavalaye J; Booij J; Reneman L; Habraken JB; van Royen EA
    Eur J Nucl Med; 2000 Jul; 27(7):867-9. PubMed ID: 10952500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone].
    Mateos JJ; Lomeña F; Parellada E; Font M; Fernández E; Pavia J; Prats A; Bernardo M
    Rev Esp Med Nucl; 2006; 25(3):159-65. PubMed ID: 16762269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.
    Lavalaye J; Linszen DH; Booij J; Dingemans PM; Reneman L; Habraken JB; Gersons BP; van Royen EA
    Schizophr Res; 2001 Jan; 47(1):59-67. PubMed ID: 11163545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease.
    Varrone A; Pellecchia MT; Amboni M; Sansone V; Salvatore E; Ghezzi D; Garavaglia B; Brice A; Brunetti A; Bonavita V; De Michele G; Salvatore M; Pappatà S; Barone P
    Neurology; 2004 Dec; 63(11):2097-103. PubMed ID: 15596756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of 123I-FP-CIT in the clinical practice in Parkinsonism patients].
    Ortega Lozano SJ; Martínez Del Valle Torres MD; Jiménez-Hoyuela García JM; Delgado García A; Campos Arillo V
    Rev Esp Med Nucl; 2005; 24(4):224-33. PubMed ID: 16122406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease.
    Covelli EM; Brunetti A; Di Lauro A; Sullo P; Mazzarella G; Tedeschi E; Belfiore G
    Radiol Med; 2004 Oct; 108(4):417-25. PubMed ID: 15525895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.